Neuland Laboratories Ltd - NEULAND LABS. Share Price

Sector: Pharmaceuticals | ISIN: INE794A01010
₹ 7,161.95 (0.84%) icon29 Feb, 2024, 3:52:11 PM
Open
₹ 7,095.00
Prev. Close
₹ 7,102.30
Turnover(lac)
₹ 0.04
Day's High
₹ 7,251.00
Day's Low
₹ 6,828.05
52 Wk High
₹ 7,318.30
52 Wk Low
₹ 1,565.00
Book Value
₹ 950.47
Face Value
₹ 10.00
Mkt. Cap (Cr.)
₹ 9,188.70
P/E
28.79
EPS
246.69
Div. Yield
0.14

Neuland Laboratories Ltd Stock View

info icon
Edit Image
STRONG BUY
Target | 10 Feb, 2024 7,500 (5.60%)

Neuland Laboratories Limited is an India-based company, which is engaged in manufacturing and selling of bulk drugs. The Company caters to both domestic and international markets. It manufac... Read More

Neuland Laboratories Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 2/29/2024 3:52:11 PM

    ₹ 7161.95 59.65 0.84
  • Open
  • ₹ 7,095
  • Prev. Close
  • ₹ 7,102.3
  • Turnover(Lac.)
  • ₹ 4,122
  • Day's High
  • ₹ 7,251
  • Day's Low
  • ₹ 6,828.05
  • 52 Week's High
  • ₹ 7,318.3
  • 52 Week's Low
  • ₹ 1,565
  • Book Value
  • ₹ 950.47
  • Face Value
  • ₹ 10
  • Mkt Cap (₹ Cr.)
  • 9,188.7
  • P/E
  • 28.79
  • EPS
  • 246.69
  • Divi. Yield
  • 0.14

Neuland Laboratories Ltd Corporate Actions

25 Jan , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

25 Jan , 2024

12:00 AM

25 Jan , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

10 Nov , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

11 Oct , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

11 Oct , 2023

12:00 AM

10 Jul , 2023

12:00 AM

10 Jul , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

11 May , 2023

12:00 AM

AGM

Announcement date: 11 May , 2023

View Details

11 May , 2023

12:00 AM

Dividend

Dividend amount: 10
Announcement date: 11 May , 2023

View Details

27 Jun , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

14 Apr , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

14 Apr , 2023

12:00 AM

11 May , 2023

12:00 AM

BookCloser

View Details

Neuland Laboratories Ltd News and Update

Image not found
  • 27 February, 2024 |
  • 12:13 AM

A press release issued by One97 Communications Ltd highlighted the appointment of several new members to the PPBL Board

Image not found
Image not found
  • IIFL News Service |
  • 23 February, 2024 |
  • 12:07 AM
Image not found
  • IIFL News Service |
  • 22 February, 2024 |
  • 12:06 AM

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Neuland Laboratories Ltd SHAREHOLDING SNAPSHOT
29 February , 2024 | 05:01 PM

PROMOTER - TOTAL32.80%

Indian: 32.80%

Foreign: 0.0016%

NON-PROMOTER - TOTAL 67.20%

Institutions: 29.12%

Non-Institutions: 38.08%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details
ad IconAd Image

Neuland Laboratories Ltd FINANCIALS

Neuland Laboratories Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Neuland Laboratories Ltd

  • D R Rao
  • Executive Chairman
  • H Dhanrajgir
  • Independent Director
  • P V Maiya
  • Independent Director
  • Christopher M Cimarusti
  • Director
  • D Sucheth Rao
  • Vice Chairman & CEO
  • D Saharsh Rao
  • Vice Chairman & M.D.
  • Sarada Bhamidipati
  • Company Sec. & Compli. Officer
  • Bharati Rao
  • Independent Director
  • Nirmala Murthy
  • Independent Director
  • Homi Rustam Khusrokhan
  • Independent Director
  • Prasad R Menon
  • Independent Director
  • Sugata Sircar
  • Independent Director
  • Pallavi Joshi Bakhru
  • Independent Director

Summary

Set up in 1984 as a private limited company to manufacture bulk drugs, Neuland Laboratories (NLL) is promoted by Davuluri Sucheth Rao. Neuland Drugs & Pharmaceuticals Pvt Ltd, a company set up by the same promoters to manufacture bulk drugs was merged with NLL with effect from Apr.92. NLL manufactures bulk drugs such as salbutamol sulphate, terbutaline sulphate, labetalol hydrochloride and ciprofloxacin. The Company came out with its initial public offering in Apr.94 at a premium of Rs 35 aggregating Rs 5.69 cr, to part-finance the capacity expansion to manufacture bulk drugs and to diversify its product-mix. The cost of the project as estimated by ICICI was Rs 15.7 cr.NLLs products are exported to more than 35 countries including Germany, Italy, Switzerland, the UK and the Netherlands. The company is also negotiating with multinational companies for tying up supplies of Ranitidine Hydrochloride Form I and Salbutamol Sulphate.During the year 1999-2000, the company introduced Itraconazole, an anti-fungal drug and Ipratropium Bromide, an anti-asthmatic drug and the R & D has developed a process for manufacture of Oflaxacin for Regulatory Markets. The Pashamylaram unit has received USFDA approval for manufacturing of Rantidine Hydrochloride Form.Mirtrazapine, an anti-depressive drug and Ramipril a cardiovascular drug were introduced during the year 2001.The installed capacities of Ciprofloxacin and Ranitidine were increased with Rs.650 lacs financial assisitance from IDBI.The... Read More


Reports by Neuland Laboratories Ltd


Reports by Neuland Laboratories Ltd

Company FAQ

No Record Found